| 摘要 |
PROBLEM TO BE SOLVED: To provide a prevention or a pharmaceutical composition for the treatment of TGFBI (transforming growth factor, beta-induced) gene mutation corneal dystrophy. SOLUTION: The pharmaceutical composition containing a lithium salt, suppresses the expression of mutant TGFBI protein, activates an auto fuzzy route, and not only selectively decomposition eliminates mutant TGFBI protein but adjusts the oxide type stress of corneal cells. The pharmaceutical composition, therefore, is very useful for prevention and treatment of TGFBI gene mutation corneal dystrophy. The lithium salt is selected from lithium carbonate (Li<SB POS="POST">2</SB>SO<SB POS="POST">3</SB>), lithium citrate, lithium sulfate (Li<SB POS="POST">2</SB>SO<SB POS="POST">4</SB>), lithium aspartate, lithium orotate, lithium chloride (LiCl), and lithium acetate. COPYRIGHT: (C)2012,JPO&INPIT |
